Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects
Cystic fibrosis (CF) is a genetic disorder that causes multiorgan morbidity and premature death, most commonly from pulmonary dysfunction. Mutations in the CF transmembrane conductance regulator (CFTR) gene, of which almost 2000 have been described, result in a dysfunctional CFTR protein. This prote...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publishing
2015-12-01
|
| Col·lecció: | Therapeutic Advances in Respiratory Disease |
| Accés en línia: | https://doi.org/10.1177/1753465815601934 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|